$171.18
0.34% day before yesterday
Nasdaq, Nov 26, 10:06 pm CET

Repligen Corporation Stock price

$171.18
+10.08 6.26% 1M
+53.03 44.88% 6M
+27.24 18.92% YTD
+24.44 16.66% 1Y
-0.46 0.27% 3Y
-10.25 5.65% 5Y
+142.64 499.79% 10Y
+168.14 5,530.92% 20Y
Nasdaq, Closing price Wed, Nov 26 2025
-0.58 0.34%

New AI Insights on Repligen Corporation Insights AI Insights on Repligen Corporation

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$9.6b
Enterprise Value
$9.4b
Net debt
positive
Cash
$748.8m
Shares outstanding
56.3m
Valuation (TTM | estimate)
P/E
5,706.0 | 100.5
P/S
13.6 | 12.9
EV/Sales
13.3 | 12.6
EV/FCF
88.5
P/B
4.6
Financial Health
Equity Ratio
69.7%
Return on Equity
-1.3%
ROCE
1.7%
ROIC
0.8%
Debt/Equity
0.3
Financials (TTM | estimate)
Revenue
$707.9m | $745.5m
EBITDA
$111.0m | $146.7m
EBIT
$46.6m | $100.4m
Net Income
$1.7m | $95.8m
Free Cash Flow
$106.5m
Growth (TTM | estimate)
Revenue
-8.5% | 17.5%
EBITDA
12.2% | 79.5%
EBIT
163.2% | 732.3%
Net Income
111.6% | 475.7%
Free Cash Flow
-18.9%
Margin (TTM | estimate)
Gross
51.6%
EBITDA
15.7% | 19.7%
EBIT
6.6%
Net
0.3% | 12.9%
Free Cash Flow
15.0%
More
EPS
$0.0
FCF per Share
$1.9
Short interest
8.0%
Employees
2k
Rev per Employee
$360.0k
Show more

Is Repligen Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.

Repligen Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

28 Analysts have issued a Repligen Corporation forecast:

22x Buy
79%
6x Hold
21%

Analyst Opinions

28 Analysts have issued a Repligen Corporation forecast:

Buy
79%
Hold
21%

Financial data from Repligen Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
708 708
9% 9%
100%
- Direct Costs 343 343
11% 11%
48%
365 365
6% 6%
52%
- Selling and Administrative Expenses 276 276
13% 13%
39%
- Research and Development Expense 52 52
1% 1%
7%
111 111
12% 12%
16%
- Depreciation and Amortization 64 64
21% 21%
9%
EBIT (Operating Income) EBIT 47 47
163% 163%
7%
Net Profit 1.74 1.74
112% 112%
0%

In millions USD.

Don't miss a Thing! We will send you all news about Repligen Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Repligen Corporation Stock News

Neutral
GlobeNewsWire
one day ago
WALTHAM, Mass., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participate in the 8th Annual Evercore Healthcare Conference, being held December 2 -4 in Coral Gables, Florida. Jason Garland, Chief Financial Officer, will participate in an analyst-led discussion on Decem...
Neutral
Seeking Alpha
9 days ago
Repligen Corporation ( RGEN ) 7th Annual Wolfe Research Healthcare Conference November 18, 2025 12:40 PM EST Company Participants Jason Garland - CFO & Chief Compliance Officer Steven Chehames Conference Call Participants Douglas Schenkel - Wolfe Research, LLC Presentation Douglas Schenkel Wolfe Research, LLC All right. Good afternoon, everybody.
Neutral
Seeking Alpha
9 days ago
Repligen Corporation ( RGEN ) Jefferies London Healthcare Conference 2025 November 18, 2025 8:30 AM EST Company Participants Olivier Loeillot - President, CEO & Director Conference Call Participants Matthew Stanton - Jefferies LLC, Research Division Presentation Matthew Stanton Jefferies LLC, Research Division Thanks. My name is Matt Stanton.
More Repligen Corporation News

Company Profile

Repligen Corp. provides advanced bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. The firm serves through the following product lines: Chromatography; Filtration; and OEM Products (Proteins). The Chromatography product line includes a number of products used in the downstream purification and quality control of biological drugs. The Filtration products offer a number of advantages to manufacturers of biologic drugs at volumes that span from pilot studies to clinical and commercial-scale production. The OEM products are represented by Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification, and cell culture growth factor products. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.

Head office United States
CEO Olivier Loeillot
Employees 1,778
Founded 1981
Website www.repligen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today